‘No More Questions’ On Scrutiny As EU Talks Set To Give Notified Bodies Yet More Responsibility
This article was originally published in Clinica
While it is premature to speak of agreement, it seems that the three parties involved in negotiating the future EU medtech regulations have reached a point where there are “no outstanding questions any more” on one of the biggest sticking points – the scrutiny of high-risk medical devices. However, Clinica understands that this is not yet the case for scrutiny of in vitro diagnostics.
You may also be interested in...
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.
2020 is not getting off to a good start for manufacturers needing to comply with the EU’s new Medical Device Regulation on 26 May 2020. The European Commission’s latest document seems to confirm industry’s fears about the ability of the EU’s medtech system to be ready in time.
December 2019 was a big month for far-reaching EU medtech regulatory developments that will have a significant impact on the way and speed of implementation of the Medical Device Regulation.